Navigation Links
IDM Pharma Reports 2008 Financial Results
Date:3/31/2009

year ended periods were to record the change in the fair value of warrants issued in February and June 2007.

The foreign exchange gain, which results from changes in the value of the dollar versus the Euro on the dollar denominated inter-company loan between the Company's subsidiaries, was $0.1 million in the fourth quarter of 2008, compared to a foreign exchange loss of $0.4 million in the fourth quarter of 2007. This foreign exchange loss was $0.1 million in the year ended December 31, 2008, compared to $1.7 million in the year ended December 31, 2007.

Net loss for the fourth quarter of 2008 was $1.9 million, or $0.07 per basic and diluted share, compared to a net loss of $2.7 million, or $0.11 per share in the corresponding period in 2007. Net loss for the year ended December 31, 2008 was $18.6 million, or $0.74 per basic and diluted loss per share compared to a net loss of $18.4 million, or $0.87 per share in the year ended December 31, 2007.

About IDM Pharma

IDM Pharma is focused on the development of innovative cancer products that either destroy cancer cells by activating the immune system or prevent tumor recurrence by triggering a specific adaptive immune response. IDM Pharma is dedicated to maximizing the full therapeutic and commercial potential of each of its innovative products to address the needs of patients and the physicians who treat these patients.

For more information about the company and its products, visit www.idm-pharma.com.

Forward-Looking Statements

This press release includes forward-looking statements that reflect management's current views of future events including statements regarding the Company's ability to deliver near-term value to its stockholders, completion of pre-launch activities and marketing of MEPACT in the EU, the timeframe in which the Compa
'/>"/>

SOURCE IDM Pharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Endo Pharmaceuticals Appoints Dr. Nancy Hutson to Board of Directors
2. The MedZilla Report: Febraury 2009 Employment Outlook for Biotech/Pharma/Health
3. Recent Graduates Finding BioTech & Pharmaceutical Jobs Easier Than Ever With The Launch of CampusRXBio
4. VIA Pharmaceuticals Complies With NASDAQ Rules
5. Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2008 Financial Results
6. Anadys Pharmaceuticals to Present at Future Leaders in the Biotech Industry
7. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at BioCentury Publications Inc. Future Leaders in the Biotech Industry Conference in New York on April 2, 2009
8. WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results
9. Trubion Pharmaceuticals, Inc. Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Systemic Lupus Erythematosus (SLE)
10. Isis Pharmaceuticals to Present at the 4th Annual Citi Biotech Day
11. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 2014 Mathematic studies at the Program for ... funded by the Jeffrey Epstein VI Foundation , have ... visually identified for elimination. These aggressive cells are the driver ... a topological map of what to look for when examining ... while tumor cells can be extracted from biopsy, it,s very ...
(Date:8/21/2014)... Sofia, Bulgaria (PRWEB) August 21, 2014 ... was released today by Ontotext . Now ... and semantic analysis of structured and unstructured data is ... of the cost of enterprise technology. Organizations that do ... approaches for data management can use S4 since there ...
(Date:8/20/2014)... licensed to biotechnology firms has revealed early bottlenecks ... roadblocks, the researchers suggest that better communication of ... lead to faster commercialization down the road. , ... in university laboratories and licensed to biotechnology firms. ... have a high failure rate. But a new ...
(Date:8/20/2014)... Mass. , Aug. 20, 2014  Decision Resources Group finds ... , Russia , India ... $1.6 billion in 2013, roughly equal to the size of ... however, the BRIC market will experience much faster growth as a ... aging population. Other key findings from Decision Resources Group,s ...
Breaking Biology Technology:Science Power Jeffrey Epstein and Harvard University Fund Project to Visually Stop Tumor Growth 2Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 2Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 3Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 4Early bottlenecks in developing biopharmaceutical products delay commercialization 2Early bottlenecks in developing biopharmaceutical products delay commercialization 3BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 2BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 3
... ROCKVILLE, Md., Jan. 9, 2012  Neuralstem, Inc. (NYSE Amex: ... Richard Garr will present at the 2012 Biotech Showcase ... Garr will serve on the Therapeutic Focus Panel entitled, ... Alliance for Regenerative Medicine (ARM) Insight Track. Garr will ...
... WOBURN, Mass., Jan. 9, 2012 Advanstar|CBI recently announced ... and Access Programs. The Forum takes place March 6-7, ... includes leading experts from Eli Lilly, Genentech, AstraZeneca, Shire ... Patient Assistance Pavilion participant Needy Meds recently interviewed PAP,s ...
... Jan. 9, 2012   Veracyte, Inc ., a ... molecular cytology, today announced that Palmetto GBA, a ... coverage for the company,s Afirma Gene Expression Classifier ... that Veracyte,s genomic test is now accessible to ...
Cached Biology Technology:Neuralstem President and CEO to Update Ongoing ALS and NSI-189/Major Depressive Disorder Trials at 2012 Biotech Showcase 2Neuralstem President and CEO to Update Ongoing ALS and NSI-189/Major Depressive Disorder Trials at 2012 Biotech Showcase 3Veracyte Announces Medicare Coverage for Its Afirma® Gene Expression Classifier for Improved Thyroid Nodule Diagnosis 2Veracyte Announces Medicare Coverage for Its Afirma® Gene Expression Classifier for Improved Thyroid Nodule Diagnosis 3
(Date:8/21/2014)... researchers at Louisiana Tech University has developed ... 3D printers and materials to fabricate custom ... chemotherapeutic compounds for targeted drug delivery. , ... research faculty from Louisiana Tech,s biomedical engineering ... filament extruders that can make medical-quality 3D ...
(Date:8/20/2014)... pregnant teenagers in Rochester, NY, nearly half engaged in ... cornstarch, vacuum dust, baby powder and soap, and other ... such teens had significantly lower iron levels as compared ... Pregnant teens, regardless of pica, are at higher risk ... and anemia. Low iron in pregnant teens raises the ...
(Date:8/20/2014)... are visible in in this image of the Para ... these were most likely intentionally set in order to ... forest or stand of trees where the land is ... include conversion of forestland to farms, ranches, or urban ... green of the Amazon Rainforest in the middle of ...
Breaking Biology News(10 mins):Louisiana Tech University researchers use 3D printers to create custom medical implants 2Louisiana Tech University researchers use 3D printers to create custom medical implants 3Pica in pregnant teens linked to low iron 2
... trees that once characterized expansive tracts of tropical rainforest ... Just how big a role these winged gardeners play ... at Chicago and several Latin American universities are about ... laboratory in Mexico's gulf coast state of Veracruz. , ...
... plants such as corn, soybeans and sunflowers into fuel ... biodiesel generates, according to a new Cornell University and ... energy benefit to using plant biomass for liquid fuel," ... Cornell. "These strategies are not sustainable." , Pimentel and ...
... structural details of a family of mysterious objects called ... of bacteria. The discovery was published Aug. 5 in ... at how microcompartments are built, and what the pieces ... chemistry and biochemistry, and a member of the UCLA-DOE ...
Cached Biology News:Birds and bats sow tropical seeds 2Birds and bats sow tropical seeds 3Ethanol and biodiesel from crops not worth the energy 2New discovery blurs distinction between human cells and those of bacteria 2New discovery blurs distinction between human cells and those of bacteria 3
synphilin-1 (V-19)...
... contains the basic components required for the ... and recombinant canine Monocyte Chemotactic Protein 1 ... Each kit contains sufficient materials to run ... that the following conditions are met:2 ...
... MaV203 Competent Yeast Cells are designed for ... 1). S. cerevisiae strain MaV203 contains deletions ... for use with GAL4-based two-hybrid systems. The ... for selection of ProQuest bait and prey ...
Anti-Cullin-1 Host: rabbit polyclonal Species Reactivity: human, mouse Applications: IHC(P), WB, IP Storage: 4C...
Biology Products: